Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Sunday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Stock Performance

CHEK opened at $1.41 on Friday. The firm’s fifty day moving average is $1.88 and its two-hundred day moving average is $2.10. The firm has a market cap of $8.25 million, a PE ratio of -0.47 and a beta of 0.39. Check-Cap has a twelve month low of $1.40 and a twelve month high of $4.59.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.